vs

Side-by-side financial comparison of LivaNova PLC (LIVN) and Madison Square Garden Sports Corp. (MSGS). Click either name above to swap in a different company.

Madison Square Garden Sports Corp. is the larger business by last-quarter revenue ($403.4M vs $360.9M, roughly 1.1× LivaNova PLC). LivaNova PLC runs the higher net margin — 8.6% vs 2.0%, a 6.5% gap on every dollar of revenue. On growth, Madison Square Garden Sports Corp. posted the faster year-over-year revenue change (12.8% vs 12.1%). LivaNova PLC produced more free cash flow last quarter ($50.2M vs $31.6M). Over the past eight quarters, LivaNova PLC's revenue compounded faster (10.6% CAGR vs -3.1%).

LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".

Madison Square Garden Sports Corp. is an American sports holding company based in New York City.

LIVN vs MSGS — Head-to-Head

Bigger by revenue
MSGS
MSGS
1.1× larger
MSGS
$403.4M
$360.9M
LIVN
Growing faster (revenue YoY)
MSGS
MSGS
+0.6% gap
MSGS
12.8%
12.1%
LIVN
Higher net margin
LIVN
LIVN
6.5% more per $
LIVN
8.6%
2.0%
MSGS
More free cash flow
LIVN
LIVN
$18.6M more FCF
LIVN
$50.2M
$31.6M
MSGS
Faster 2-yr revenue CAGR
LIVN
LIVN
Annualised
LIVN
10.6%
-3.1%
MSGS

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
LIVN
LIVN
MSGS
MSGS
Revenue
$360.9M
$403.4M
Net Profit
$30.9M
$8.2M
Gross Margin
65.2%
Operating Margin
11.8%
5.5%
Net Margin
8.6%
2.0%
Revenue YoY
12.1%
12.8%
Net Profit YoY
-44.7%
641.9%
EPS (diluted)
$0.57
$0.34

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LIVN
LIVN
MSGS
MSGS
Q4 25
$360.9M
$403.4M
Q3 25
$357.8M
$39.5M
Q2 25
$352.5M
$204.0M
Q1 25
$316.9M
$424.2M
Q4 24
$321.8M
$357.8M
Q3 24
$318.1M
$53.3M
Q2 24
$318.6M
$227.3M
Q1 24
$294.9M
$430.0M
Net Profit
LIVN
LIVN
MSGS
MSGS
Q4 25
$30.9M
$8.2M
Q3 25
$26.8M
$-8.8M
Q2 25
$27.2M
$-1.8M
Q1 25
$-327.3M
$-14.2M
Q4 24
$55.9M
$1.1M
Q3 24
$33.0M
$-7.5M
Q2 24
$16.3M
$25.5M
Q1 24
$-41.9M
$37.9M
Gross Margin
LIVN
LIVN
MSGS
MSGS
Q4 25
65.2%
Q3 25
68.4%
Q2 25
67.8%
Q1 25
69.7%
Q4 24
68.2%
Q3 24
70.8%
Q2 24
68.7%
Q1 24
70.3%
Operating Margin
LIVN
LIVN
MSGS
MSGS
Q4 25
11.8%
5.5%
Q3 25
15.1%
-69.5%
Q2 25
15.4%
-11.1%
Q1 25
15.3%
7.6%
Q4 24
11.5%
3.7%
Q3 24
11.2%
-15.5%
Q2 24
12.6%
23.0%
Q1 24
5.5%
18.5%
Net Margin
LIVN
LIVN
MSGS
MSGS
Q4 25
8.6%
2.0%
Q3 25
7.5%
-22.3%
Q2 25
7.7%
-0.9%
Q1 25
-103.3%
-3.4%
Q4 24
17.4%
0.3%
Q3 24
10.4%
-14.1%
Q2 24
5.1%
11.2%
Q1 24
-14.2%
8.8%
EPS (diluted)
LIVN
LIVN
MSGS
MSGS
Q4 25
$0.57
$0.34
Q3 25
$0.49
$-0.37
Q2 25
$0.50
$-0.08
Q1 25
$-6.01
$-0.59
Q4 24
$1.04
$0.05
Q3 24
$0.60
$-0.31
Q2 24
$0.30
$1.07
Q1 24
$-0.78
$1.57

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LIVN
LIVN
MSGS
MSGS
Cash + ST InvestmentsLiquidity on hand
$635.6M
$81.3M
Total DebtLower is stronger
$376.1M
Stockholders' EquityBook value
$1.2B
$-282.1M
Total Assets
$2.6B
$1.5B
Debt / EquityLower = less leverage
0.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LIVN
LIVN
MSGS
MSGS
Q4 25
$635.6M
$81.3M
Q3 25
$646.1M
$48.6M
Q2 25
$593.6M
$144.6M
Q1 25
$738.4M
$96.5M
Q4 24
$428.9M
$107.8M
Q3 24
$346.4M
$52.3M
Q2 24
$329.2M
$89.1M
Q1 24
$309.2M
$40.0M
Total Debt
LIVN
LIVN
MSGS
MSGS
Q4 25
$376.1M
Q3 25
$434.5M
Q2 25
$430.6M
Q1 25
$628.2M
Q4 24
$627.0M
Q3 24
$625.5M
Q2 24
$624.5M
Q1 24
$623.8M
Stockholders' Equity
LIVN
LIVN
MSGS
MSGS
Q4 25
$1.2B
$-282.1M
Q3 25
$1.2B
$-294.2M
Q2 25
$1.1B
$-281.4M
Q1 25
$1.0B
$-283.4M
Q4 24
$1.3B
$-273.1M
Q3 24
$1.3B
$-277.5M
Q2 24
$1.2B
$-266.3M
Q1 24
$1.2B
$-294.0M
Total Assets
LIVN
LIVN
MSGS
MSGS
Q4 25
$2.6B
$1.5B
Q3 25
$2.6B
$1.5B
Q2 25
$2.5B
$1.5B
Q1 25
$2.6B
$1.5B
Q4 24
$2.5B
$1.4B
Q3 24
$2.5B
$1.4B
Q2 24
$2.5B
$1.3B
Q1 24
$2.5B
$1.4B
Debt / Equity
LIVN
LIVN
MSGS
MSGS
Q4 25
0.31×
Q3 25
0.38×
Q2 25
0.38×
Q1 25
0.61×
Q4 24
0.47×
Q3 24
0.48×
Q2 24
0.50×
Q1 24
0.51×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LIVN
LIVN
MSGS
MSGS
Operating Cash FlowLast quarter
$82.4M
$32.4M
Free Cash FlowOCF − Capex
$50.2M
$31.6M
FCF MarginFCF / Revenue
13.9%
7.8%
Capex IntensityCapex / Revenue
8.9%
0.2%
Cash ConversionOCF / Net Profit
2.67×
3.94×
TTM Free Cash FlowTrailing 4 quarters
$173.3M
$-480.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LIVN
LIVN
MSGS
MSGS
Q4 25
$82.4M
$32.4M
Q3 25
$85.1M
$-85.0M
Q2 25
$62.9M
$49.7M
Q1 25
$24.0M
$6.3M
Q4 24
$78.7M
$61.8M
Q3 24
$51.0M
$-26.2M
Q2 24
$43.4M
$108.4M
Q1 24
$10.0M
$4.0M
Free Cash Flow
LIVN
LIVN
MSGS
MSGS
Q4 25
$50.2M
$31.6M
Q3 25
$62.2M
$-85.3M
Q2 25
$47.8M
$49.4M
Q1 25
$13.2M
$3.9M
Q4 24
$68.3M
$61.2M
Q3 24
$32.8M
$-26.5M
Q2 24
$31.2M
$108.0M
Q1 24
$3.6M
$3.9M
FCF Margin
LIVN
LIVN
MSGS
MSGS
Q4 25
13.9%
7.8%
Q3 25
17.4%
-216.3%
Q2 25
13.6%
24.2%
Q1 25
4.2%
0.9%
Q4 24
21.2%
17.1%
Q3 24
10.3%
-49.7%
Q2 24
9.8%
47.5%
Q1 24
1.2%
0.9%
Capex Intensity
LIVN
LIVN
MSGS
MSGS
Q4 25
8.9%
0.2%
Q3 25
6.4%
0.9%
Q2 25
4.3%
0.2%
Q1 25
3.4%
0.6%
Q4 24
3.2%
0.1%
Q3 24
5.7%
0.7%
Q2 24
3.8%
0.2%
Q1 24
2.2%
0.0%
Cash Conversion
LIVN
LIVN
MSGS
MSGS
Q4 25
2.67×
3.94×
Q3 25
3.18×
Q2 25
2.32×
Q1 25
Q4 24
1.41×
55.61×
Q3 24
1.55×
Q2 24
2.65×
4.25×
Q1 24
0.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LIVN
LIVN

Other$169.4M47%
Neuromodulation Segment$119.7M33%
Cardiopulmonary Segment$71.8M20%

MSGS
MSGS

Event Related$167.2M41%
Media Rights$122.3M30%
Sponsorship Signage And Suite Licenses$98.5M24%
League Distribution$15.4M4%

Related Comparisons